Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial

Andrew Duncan Steele, Kathleen M Neuzil, Nigel A Cunliffe, Shabir A Madhi, Pieter Bos, Bagrey Ngwira, Desiree Witte, Stacy Todd, Cheryl Louw, Mari Kirsten, Sanet Aspinall, Leen Jan Van Doorn, Alain Bouckenooghe, Pemmaraju V Suryakiran, Htay Htay Han, Andrew Duncan Steele, Kathleen M Neuzil, Nigel A Cunliffe, Shabir A Madhi, Pieter Bos, Bagrey Ngwira, Desiree Witte, Stacy Todd, Cheryl Louw, Mari Kirsten, Sanet Aspinall, Leen Jan Van Doorn, Alain Bouckenooghe, Pemmaraju V Suryakiran, Htay Htay Han

Abstract

Background: Rotaviruses are the most important cause of severe acute gastroenteritis worldwide in children <5 years of age. The human, G1P[8] rotavirus vaccine Rotarix™ significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy in preventing severe rotavirus gastroenteritis, during infancy, caused by the various G and P rotavirus types encountered during the first rotavirus-season.

Methods: Healthy infants aged 5-10 weeks were enrolled and randomized into three groups to receive either two (10 and 14 weeks) or three doses of Rotarix™ (together forming the pooled Rotarix™ group) or three doses of placebo at a 6,10,14-week schedule. Weekly home visits were conducted to identify gastroenteritis episodes. Rotaviruses were detected by ELISA and genotyped by RT-PCR and nucleotide sequencing. The percentage of infants with severe rotavirus gastroenteritis caused by the circulating G and P types from 2 weeks post-last dose until one year of age and the corresponding vaccine efficacy was calculated with 95% CI.

Results: Overall, 4939 infants were vaccinated and 4417 (pooled Rotarix™ = 2974; placebo = 1443) were included in the per protocol efficacy cohort. G1 wild-type was detected in 23 (1.6%) severe rotavirus gastroenteritis episodes from the placebo group. This was followed in order of detection by G12 (15 [1%] in placebo) and G8 types (15 [1%] in placebo). Vaccine efficacy against G1 wild-type, G12 and G8 types were 64.1% (95% CI: 29.9%; 82%), 51.5% (95% CI:-6.5%; 77.9%) and 64.4% (95% CI: 17.1%; 85.2%), respectively. Genotype P[8] was the predominant circulating P type and was detected in 38 (2.6%) severe rotavirus gastroenteritis cases in placebo group. The remaining circulating P types comprised of P[4] (20 [1.4%] in placebo) and P[6] (13 [0.9%] in placebo). Vaccine efficacy against P[8] was 59.1% (95% CI: 32.8%; 75.3%), P[4] was 70.9% (95% CI: 37.5%; 87.0%) and P[6] was 55.2% (95% CI: -6.5%; 81.3%)

Conclusions: Rotarix™ vaccine demonstrated efficacy against severe gastroenteritis caused by diverse circulating rotavirus types. These data add to a growing body of evidence supporting heterotypic protection provided by Rotarix™.

Trial registration number: NCT00241644.

Figures

Figure 1
Figure 1
Distribution of major rotavirus strains in placebo groups for South Africa and Malawi. Figure obtained from Supplement to: Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289-98.

References

    1. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec. 2007;82:285–296.
    1. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D. et al.Global mortality associated with rotavirus disease among children in 2004. J Infect Dis. 2009;200:S9–S15. doi: 10.1086/605025.
    1. World Health Organization. Rotavirus vaccination. Wkly Epidemiol Rec. 2009;84:213–236.
    1. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C. et al.Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–298. doi: 10.1056/NEJMoa0904797.
    1. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR. et al.Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–614. doi: 10.1016/S0140-6736(10)60889-6.
    1. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ. et al.Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615–623. doi: 10.1016/S0140-6736(10)60755-6.
    1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC. et al.Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434.
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z. et al.Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. doi: 10.1056/NEJMoa052664.
    1. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R. et al.Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757–1763. doi: 10.1016/S0140-6736(07)61744-9.
    1. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F. et al.Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1181–1189. doi: 10.1016/S0140-6736(08)60524-3.
    1. Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak SH. et al.Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomized, double-blind, controlled study. Vaccine. 2009;27:5936–5941. doi: 10.1016/j.vaccine.2009.07.098.
    1. De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R. et al.Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes integrated analysis of randomized controlled trials. Pediatr Infect Dis J. 2009;28:261–266. doi: 10.1097/INF.0b013e3181907177.
    1. Offit PA, Clark HF, Blavat G, Greenberg HB. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. J Virol. 1986;60(2):491–496.
    1. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M. et al.Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005;192(Suppl 1):S146–S159.
    1. Kirkwood CD, Boniface K, Bogdanovic-Sakran N, Masendycz P, Barnes GL, Bishop RF. Rotavirus strain surveillance–an Australian perspective of strains causing disease in hospitalised children from 1997 to 2007. Vaccine. 2009;27(Suppl 5):F102–F107.
    1. Page NA, Steele AD. Antigenic and genetic characterization of serotype G2 human rotavirus strains from South Africa from 1984 to 1998. J Med Virol. 2004;72(2):320–327. doi: 10.1002/jmv.10571.
    1. Cunliffe NA, Gondwe JS, Broadhead RL, Molyneux ME, Woods PA, Bresee JS. et al.Rotavirus G and P types in children with acute diarrhea in Blantyre, Malawi, from 1997 to 1998: predominance of novel P[6]G8 strains. J Med Virol. 1999;57(3):308–312. doi: 10.1002/(SICI)1096-9071(199903)57:3<308::AID-JMV15>;2-B.
    1. Fischer TK, Page NA, Griffin DD, Eugen-Olsen J, Pedersen AG, Valentiner-Branth P. et al.Characterization of incompletely typed rotavirus strains from Guinea-Bissau: identification of G8 and G9 types and a high frequency of mixed infections. Virology. 2003;311(1):125–133. doi: 10.1016/S0042-6822(03)00153-3.
    1. Steele AD, Nimzing L, Peenze I, de Beer MC, Geyer A, Angyo I, Gomwalk NE. Circulation of the novel G9 and G8 rotaviruses in Nigeria in 1998/1999. J Med Virol. 2002;67:608–612. doi: 10.1002/jmv.10146.
    1. Esona MD, Geyer A, Page N, Trabelsi A, Fodha I, Aminu M. et al.Genomic characterization of human rotavirus G8 strains from the African rotavirus network: relationship to animal rotaviruses. J Med Virol. 2009;81(5):937–951. doi: 10.1002/jmv.21468.
    1. Page N, Esona M, Seheri M, Nyangao J, Bos P, Mwenda J. et al.Characterization of genotype G8 strains from Malawi, Kenya, and South Africa. J Med Virol. 2010;82(12):2073–2081. doi: 10.1002/jmv.21912.
    1. Gouvea V, de Castro L, Timenetsky MC, Greenberg H, Santos N. Rotavirus serotype G5 associated with diarrhea in Brazilian children. J Clin Microbiol. 1994;32(5):1408–1409.
    1. Gómara MI, Kang G, Mammen A, Jana AK, Abraham M, Desselberger U. et al.Characterization of G10P[11] rotaviruses causing acute gastroenteritis in neonates and infants in Vellore, India. J Clin Microbiol. 2004;42:2541–2547. doi: 10.1128/JCM.42.6.2541-2547.2004.
    1. Cunliffe NA, Ngwira BM, Dove W, Nakagomi O, Nakagomi T, Perez A. et al.Serotype G12 rotaviruses, Lilongwe, Malawi. Emerg Infect Dis. 2009;15:87–90. doi: 10.3201/eid1501.080427.
    1. Page NA, de Beer MC, Seheri LM, Dewar JB, Steele AD. The detection and molecular characterization of human G12 genotypes in South Africa. J Med Virol. 2009;81:106–113. doi: 10.1002/jmv.21362.
    1. Iturriza-Gómara M, Green J, Brown DW, Desselberger U, Gray JJ. Diversity within the VP4 gene of rotavirus P[8] strains: implications for reverse transcription-PCR genotyping. J Clin Microbiol. 2000;38(2):898–901.
    1. Esona MD, Steele D, Kerin T, Armah G, Peenze I, Geyer A. et al.Determination of the G and P types of previously nontypeable rotavirus strains from the African Rotavirus Network, 1996–2004: Identification of unusual G types. J Infect Dis. 2010;202(Suppl):49–54.
    1. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996–1999: emergence of G9 strains and P[6] strains. Vaccine. 2003;21:361–367. doi: 10.1016/S0264-410X(02)00616-3.
    1. Sanchez-Padilla E, Grais RF, Guerin PJ, Steele AD, Burny ME, Luquero FJ. et al.Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:567–576. doi: 10.1016/S1473-3099(09)70179-3.
    1. Todd S, Page NA, Steele AD, Peenze I, Cunliffe NA. Rotavirus strain types circulating in Africa: Review of studies published during 1997–2006. J Infect Dis. 2010;202(Suppl):S34–S42.
    1. O’Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines. 2007;6:11–19. doi: 10.1586/14760584.6.1.11.
    1. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrheal episodes. Scand J Infect Dis. 1990;22:259–267. doi: 10.3109/00365549009027046.
    1. van Doorn LJ, Kleter B, Hoefnagel E, Stainier I, Poliszczak A, Colau B. et al.Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol. 2009;47:2704–2712. doi: 10.1128/JCM.00378-09.
    1. Neuzil KM, Armah GE, Parashar UD, Steele AD. Rotavirus in Africa: shifting the focus to disease prevention. J Infect Dis. 2010;202(Suppl):S1–S4.
    1. Mwenda JM, Ntoto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J. et al.Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010;202(Suppl):S5–S11.
    1. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis. 2009;200(Suppl 1):S28–S38.
    1. WHO, UNICEF, World Bank. State of the world’s vaccines and immunization. 3. Geneva: World Health Organization; 2009.
    1. Cunliffe NA, Gondwe JS, Graham SM, Thindwa BD, Dove W, Broadhead RL. et al.Rotavirus strain diversity in Blantyre, Malawi, from 1997 to 1999. J Clin Microbiol. 2001;39(3):836–843. doi: 10.1128/JCM.39.3.836-843.2001.
    1. Armah GE, Steele AD, Binka FN, Esona MD, Asmah RH, Anto F. et al.Changing patterns of rotavirus genotypes in Ghana: emergence of human rotavirus G9 as a major cause of diarrhea in children. J Clin Microbiol. 2003;41(6):2317–2322. doi: 10.1128/JCM.41.6.2317-2322.2003.
    1. Steele AD, Peenze I, de Beer MC, Pager CT, Yeats J, Potgieter N. et al.Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine. 2003;21:354–360. doi: 10.1016/S0264-410X(02)00615-1.
    1. Gray J, Vesikari T, Van Damme P, Giaquinto C, Mrukowicz J, Guarino A. et al.Rotavirus. J Pediatr Gastroenterol Nutr. 2008;46:S24–S31. doi: 10.1097/MPG.0b013e31816f78ee.
    1. Flores J, Perez-Schael I, Blanco M, Vilar M, Garcia D, Perez M. et al.Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. J Clin Microbiol. 1989;27(3):512–518.
    1. Ward RL, Knowlton DR, Schiff GM, Hoshino Y, Greenberg HB. Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus. J Virol. 1988;62(5):1543–1549.
    1. Ward RL. Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model. Viral Immunol. 2003;16(1):17–24. doi: 10.1089/088282403763635410.
    1. Cunliffe NA, Ngwira BM, Dove W, Thindwa BD, Turner AM, Broadhead RL. et al.Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997–2007. J Infect Dis. 2010;202(Suppl):S168–S174.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir